Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

NCT03541902 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03541902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03541902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 15, 2018
Completion date
July 31, 2027
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chromophobe renal cell carcinoma, malignant neoplasms of urinary tract, metastatic renal cell carcinoma, papillary renal cell carcinoma, renal cell carcinoma, renal cell carcinoma associated with xp11.2 translocations/tfe3 gene fusions, sarcomatoid renal cell carcinoma, stage iv renal cell cancer ajcc v8, unclassified renal cell carcinoma